Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
This bill requires that most direct-to-consumer (DTC) advertisements for FDA-approved prescription drugs and biologics covered by Medicare or Medicaid disclose the product’s wholesale acquisition cost (WAC) for a 30-day supply or typical course. Ads for products with a WAC under $35 are exempt.
Effectiveness of WAC as helpful versus misleading price metric
Relative to its intended legislative type, this bill is a focused substantive change that clearly defines the problem and prescribes a concrete disclosure requirement (WAC) with statutory definitions, a regulatory timeline, and a civil penalty; however, it leaves significant operational detail, resourcing, and enforcement design to future rulemaking without providing appropriations detail or monitoring requirements.
This bill requires that most direct-to-consumer (DTC) advertisements for FDA-approved prescription drugs and biologics covered by Medicare or Medicaid disclose the product’s wholesale acquisition cost (WAC) for a 30-day supply or typical course.
Ads for products with a WAC under $35 are exempt.
The Department of Health and Human Services must issue implementing regulations within one year, and manufacturers violating the rule may face civil penalties up to $100,000 per violation.
Moderately plausible: low fiscal cost and consumer appeal help, but strong industry lobbying, implementation complexity, and potential litigation create uncertainty.
Relative to its intended legislative type, this bill is a focused substantive change that clearly defines the problem and prescribes a concrete disclosure requirement (WAC) with statutory definitions, a regulatory timeline, and a civil penalty; however, it leaves significant operational detail, resourcing, and enforcement design to future rulemaking without providing appropriations detail or monitoring requirements.
Effectiveness of WAC as helpful versus misleading price metric
These are examples from the analysis, not a ranked list of the most-affected groups.
Effectiveness of WAC as helpful versus misleading price metric
Likely broadly supportive: sees the bill as improving consumer information and curbing wasteful federal drug spending.
Would welcome price transparency in ads but may view WAC as an imperfect metric, preferring net price or out-of-pocket estimates.
Might push for stronger measures or clearer consumer-facing cost estimates in implementing rules.
Generally supportive but pragmatic: values transparency and modest regulatory action while wanting clear, implementable rules.
Sees WAC disclosure as a reasonable first step, but wants HHS regulations to minimize confusion and avoid excessive compliance costs.
Will weigh enforcement practicality and unintended effects on patient behavior.
Likely skeptical or opposed: views the mandate as government intrusion into commercial speech and burdensome regulation on manufacturers and advertisers.
Concerns focus on free-market impacts, administrative costs, and the potential for misleading single-number disclosures that distort consumer decisions.
Prefers market-driven transparency or targeted reforms to patient cost-sharing instead.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Moderately plausible: low fiscal cost and consumer appeal help, but strong industry lobbying, implementation complexity, and potential litigation create uncertainty.
The bill has not accumulated any surfaced votes yet.
Effectiveness of WAC as helpful versus misleading price metric
Moderately plausible: low fiscal cost and consumer appeal help, but strong industry lobbying, implementation complexity, and potential liti…
Relative to its intended legislative type, this bill is a focused substantive change that clearly defines the problem and prescribes a concrete disclosure requirement (WAC) with statutory definitions, a regulatory timel…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.